In-hospital outcomes
| Outcomes | TAVR | SAVR | OR (95% CI) |
| All-cause mortality | 90 (3.41%) | 171 (1.83%) | 0.83 (0.60 to 1.15) |
| Non-cardiovascular mortality | 30 (1.14%) | 43 (0.46%) | 1.16 (0.63 to 2.13) |
| Cardiovascular mortality | 60 (2.27%) | 128 (1.37%) | 0.73 (0.50 to 1.08) |
| Ischaemic stroke | 53 (2.01%) | 122 (1.3%) | 0.90 (0.59 to 1.37) |
| Myocardial infarction | 11 (0.42%) | 23 (0.25%) | 0.84 (0.34 to 2.04) |
| Endocarditis | <6 (<0.23%)* | 60 (0.64%) | 0.15 (0.05 to 0.47) |
| Reintervention | <6 (<0.23%)* | <10 (<0.10%)* | 1.12 (0.23 to 5.36) |
| Valve complication | 69 (2.61%) | 157 (1.68%) | 1.38 (0.95 to 2.02) |
| Acute kidney injury | <6 (<0.23%)* | 26 (0.28%) | 0.27 (0.07 to 1.08) |
| Pacemaker implantation | 299 (11.32%) | 404 (4.32%) | 2.06 (1.67 to 2.53) |
| Defibrillator | <6 (<0.23%)* | 11 (0.12%) | 1.62 (0.43 to 6.16) |
| Incident atrial fibrillation | 63 (2.39%) | 729 (7.79%) | 0.24 (0.17 to 0.32) |
Multivariable logistic regression reporting OR and 95% CI of primary and secondary outcomes occurring from procedure date to date of discharge for patients undergoing TAVR versus SAVR.
*Data were suppressed due to ICES reporting policy regarding small cell (the number of events is equal to or less than 5).
ICES, Institute for Clinical Evaluative Sciences; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement.